Allergan, Inc.
http://www.allergan.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Allergan, Inc.
Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout
The acquisition of Mariana will complement Novartis’s lutetium-based radioligand therapies with candidates using actinium. Lilly, Bristol and AstraZeneca all have made recent high-priced buys in the space.
Addex Gets Creative To Secure Funding And Its Future
Addex Therapeutics’ Tim Dyer has seen the company through 22 years of ups and downs. He has kept the company afloat, and recently did the same by spinning out a new company.
J&J Tees Up Proposal To Settle Complaints Alleging Talc Caused Ovarian Cancer
J&J executives are confident the proposal to pay plaintiffs making ovarian cancer claims a total of $6.48bn over 25 years will be accepted, resolving 99.75% of those lawsuits pending against it and US affiliates. The proposal allows individual plaintiffs direct say on whether to accept it.
US FDA May User Fee Preview: Vaccines, Gene Therapy, And Double Oncologics
Five novel agents are among the user fee goal dates coming up in May 2024.
Company Information
- Industry
-
Pharmaceuticals
- OTC, Consumer
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Medical Devices
- Implantable Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
-
- Inamed
- MAP Pharmaceuticals, Inc. (MAPP)
- Oculex Pharmaceuticals, Inc.
- SkinMedica, Inc.
- Vicept
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice